Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Hymecromone by Halo Biosciences for Pulmonary Hypertension: Likelihood of Approval
Hymecromone is under clinical development by Halo Biosciences and currently in Phase II for Pulmonary Hypertension. According to GlobalData, Phase...
Hymecromone by Halo Biosciences for Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease): Likelihood of Approval
Hymecromone is under clinical development by Halo Biosciences and currently in Phase II for Interstitial Lung Diseases (Diffuse Parenchymal Lung...
Hymecromone by Halo Biosciences for Primary Sclerosing Cholangitis: Likelihood of Approval
Hymecromone is under clinical development by Halo Biosciences and currently in Phase II for Primary Sclerosing Cholangitis. According to GlobalData,...
Hymecromone by Halo Biosciences for Primary Sclerosing Cholangitis: Likelihood of Approval
Hymecromone is under clinical development by Halo Biosciences and currently in Phase II for Primary Sclerosing Cholangitis. According to GlobalData,...
Hymecromone by Halo Biosciences for Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease): Likelihood of Approval
Hymecromone is under clinical development by Halo Biosciences and currently in Phase II for Interstitial Lung Diseases (Diffuse Parenchymal Lung...